生物標記臨床階段外包服務市場規模、佔有率、趨勢分析報告：依生物標記類型、治療領域、最終用途、地區、細分市場、預測，2023-2030

Biomarker Clinical Phase Outsourcing Services Market Size, Share & Trends Analysis Report By Biomarker Type (Predictive Biomarkers, Surrogate Endpoints), By Therapeutic Area, By End-use, By Region, And Segment Forecasts, 2023 - 2030

出版日期: 2023年10月16日 | 出版商:

Grand View Research | 英文 195 Pages | 商品交期: 2-10個工作天內

價格

簡介目錄圖表

生物標記臨床階段外包服務市場成長與趨勢：

Grand View Research, Inc.最新報告顯示，預計到2030年，全球生物標記臨床階段外包服務市場規模將達到271.7億美元，複合年複合成長率為20.6%。

生物標記診斷應用的增加、組學技術的快速進步、政府研發（R&D）資金的增加以及向精準醫療的轉變是推動市場成長的一些因素。

市場分散，多個主要企業擁有相似的技術力和加工能力。這些公司提供與生物標記測試相關的各種服務，包括測定開發、樣本分析、資料解釋和臨床試驗支援。由於品質保證、技術進步、法規合規以及提供高價值和多樣化服務的能力等因素，該行業的特點是競爭激烈。

生物標記是個人化醫療的核心，可以實現更好的患者照護和更有效的治療。因此，向精準醫療的轉變也是支撐生物標記檢測服務需求、進而促進市場成長的關鍵因素之一。例如，2022年1月，輝瑞公司和Beam Therapeutics公司宣布達成為期年度的獨家合作研究協議，開發罕見遺傳疾病的精準醫療。

COVID-19 大流行對市場產生了中等影響。由於旅行限制，COVID-19 大流行的早期階段對臨床試驗產生了重大影響，包括涉及生物標記測試服務的臨床試驗。然而，由於 COVID-19 診斷生物標記的快速開拓，市場已從損失中恢復過來。基於生物標記的測試，例如針對病毒 RNA 的 PCR 檢測和檢測病毒蛋白的抗原測試，對於識別和追蹤病毒至關重要。

生物標記臨床階段外包服務市場報告亮點

按生物標記類型分類，替代終點領域佔最大佔有率，2022 年為 56.0%。該領域的成長是由於對精準醫療的需求不斷成長以及使用生物標記分析的臨床試驗數量的增加所推動的。
以治療領域來看，腫瘤學佔最大佔有率，2022年將達34.6%。該領域市場佔有率高的主要原因是用於癌症早期檢測和診斷的癌症生物標記的需求不斷增加。
隨著越來越多的生物製藥公司投資開發新型生物標記測試服務，預計生技公司在分析期間的年複合成長率將達到 20.8%。
預計亞太地區在預測期內年複合成長率最高，達 21.4%。高成長主要是由於越來越多的西方製藥公司將其製造活動外包給中國和印度等新興經濟體。

2022 年及 2030 年區域市場佔有率分析
區域市場儀表板
全球區域市場概況
北美洲
- 2018-2030 年市場估計與預測
- 美國
- 加拿大
歐洲
- 英國
- 德國
- 法國
- 義大利
- 西班牙
- 丹麥
- 瑞典
- 挪威
亞太地區
- 日本
- 印度
- 中國
- 韓國
- 澳洲
- 泰國
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
中東/非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 科威特

第8章競爭形勢

市場參與企業分類
- 創新者
- 市場領導者
- 新興玩家
- 2022 年公司市場佔有率分析
公司簡介
- Laboratory Corporation of America Holdings
- Parexel International Corporation
- ICON plc
- Charles River Laboratories
- Proteome Sciences
- Fujirebio
- WuXi AppTec
- NorthEast BioAnalytical Laboratories LLC.
- Celerion
- GenScript ProBio

簡介目錄圖表

Product Code: GVR-4-68040-138-1

Biomarker Clinical Phase Outsourcing Services Market Growth & Trends:

The global biomarker clinical phase outsourcing services market size is expected to reach USD 27.17 billion by 2030, registering a CAGR of 20.6%, according to a new report by Grand View Research, Inc.. Increasing diagnostic applications of biomarkers, rapid advancements in OMICS technologies, a rise in research and development (R&D) funding from the government, and the shift toward precision medicine are a few of the factors driving the growth of the market.

The market is fragmented, with several key players having similar technological and processing capabilities. These companies offer various services related to biomarker testing, including assay development, sample analysis, data interpretation, and clinical trial support. This industry is characterized by intense competition driven by factors such as quality assurance, technological advancements, regulatory compliance, and the ability to offer high-value and diverse services.

Biomarkers are at the core of personalized medicine, enabling better patient care and more effective treatments. Hence, the shift towards precision medicine is another significant factor supporting demand for biomarker testing services, thereby augmenting market growth. For instance, in January 2022, Pfizer Inc. and Beam Therapeutics Inc. announced an exclusive four-year research collaboration agreement to develop precision medicines for rare genetic diseases.

The COVID-19 pandemic moderately impacted the market. The initial phase of the COVID-19 pandemic has significantly affected clinical trials due to travel restrictions, including trials involving biomarker testing services. However, the market recovered from the losses due to the rapid development of biomarkers for COVID-19 diagnosis. Biomarker-based tests, such as PCR assays targeting viral RNA and antigen tests detecting viral proteins, have been crucial for identifying and tracking the virus.

Biomarker Clinical Phase Outsourcing Services Market Report Highlights:

Based on biomarker type, the surrogate endpoints segment accounted for the largest share of 56.0% in 2022. The segment's growth is driven by the growing demand for precision medicines and the rise in the number of clinical trials involving the use of biomarker analysis
Based on therapeutic area, the oncology segment accounted for the largest share of 34.6% in 2022. High segment shares are majorly due to the increasing demand for cancer biomarkers for early detection and diagnosis of the condition
Based on end-use, the biotechnology companies are anticipated to witness the highest CAGR of 20.8% across the analysis timeframe due to the increasing number of biopharmaceutical companies investing in developing novel biomarker testing services
Asia Pacific is anticipated to witness the highest CAGR of 21.4% during the forecast time frame. High growth is primarily due to increasing number of Western pharmaceutical companies outsourcing their manufacturing activities to developing economies such as China and India

Chapter 1. Research Methodology and Scope

1.1. Market Segmentation & Scope
- 1.1.1. Segment Definitions
- 1.1.2. Biomarker Type
- 1.1.3. Therapeutic Area
- 1.1.4. End-use
1.2. Regional Scope
1.3. Estimates And Forecast Timeline
1.4. Objectives
- 1.4.1. Objective-1
- 1.4.2. Objective-2
- 1.4.3. Objective-3
1.5. Research Methodology
1.6. Information Procurement
- 1.6.1. Purchased Database
- 1.6.2. GVR's Internal Database
- 1.6.3. Secondary Sources
- 1.6.4. Primary Research
1.7. Information Or Data Analysis
- 1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
- 1.9.1. Commodity Flow Analysis
- 1.9.2. Parent Market Analysis
1.10. List Of Secondary Sources
1.11. List Of Abbreviations

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. Biomarker Clinical Phase Outsourcing Services Market Variables, Trends & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
  - 3.2.1.1. Increasing diagnostic applications of biomarkers
  - 3.2.1.2. Rise in R&D funding from the government
  - 3.2.1.3. Rapid advancements in technologies such as genomics, proteomics, and imaging
  - 3.2.1.4. The shift toward precision medicine
- 3.2.2. Market Restraint Analysis
  - 3.2.2.1. High capital investment
  - 3.2.2.2. Challenges related to quality control
3.3. Biomarker Clinical Phase Outsourcing Services Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
  - 3.3.1.1. Supplier Power
  - 3.3.1.2. Buyer Power
  - 3.3.1.3. Substitution Threat
  - 3.3.1.4. Threat Of New Entrant
  - 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTEL Analysis
- 3.3.3. COVID-19 Impact Analysis

Chapter 4. Biomarker Clinical Phase Outsourcing Services Market: Biomarker Type Estimates & Trend Analysis

4.1. Biomarker Clinical Phase Outsourcing Services Market, By Biomarker Type: Segment Dashboard
4.2. Biomarker Clinical Phase Outsourcing Services Market, By Biomarker Type: Movement Analysis
4.3. Biomarker Clinical Phase Outsourcing Services Market Estimates & Forecasts, By Biomarker Type, 2018 - 2030
- 4.3.1. Predictive Biomarkers
  - 4.3.1.1. Predictive Biomarkers Clinical Phase Outsourcing Services Market, 2018 to 2030 (USD Million)
- 4.3.2. Prognostic Biomarkers
  - 4.3.2.1. Prognostic Biomarkers Clinical Phase Outsourcing Services Market, 2018 to 2030 (USD Million)
- 4.3.3. Safety Biomarkers
  - 4.3.3.1. Safety Biomarkers Clinical Phase Outsourcing Services Market, 2018 to 2030 (USD Million)
- 4.3.4. Surrogate Endpoints
  - 4.3.4.1. Surrogate Endpoints Clinical Phase Outsourcing Services Market, 2018 to 2030 (USD Million)

Chapter 5. Biomarker Clinical Phase Outsourcing Services Market: Therapeutic Area Estimates & Trend Analysis

5.1. Biomarker Clinical Phase Outsourcing Services Market, By Therapeutic Area: Segment Dashboard
5.2. Biomarker Clinical Phase Outsourcing Services Market, By Therapeutic Area: Movement Analysis
5.3. Biomarker Clinical Phase Outsourcing Services Market Estimates & Forecasts, By Therapeutic Area, 2018 - 2030
- 5.3.1. Oncology
  - 5.3.1.1. Oncology Biomarker Clinical Phase Outsourcing Services Market, 2018 to 2030 (USD Million)
- 5.3.2. Neurology
  - 5.3.2.1. Neurology Biomarker Clinical Phase Outsourcing Services Market, 2018 to 2030 (USD Million)
- 5.3.3. Cardiology
  - 5.3.3.1. Cardiology Biomarker Clinical Phase Outsourcing Services Market, 2018 to 2030 (USD Million)
- 5.3.4. Autoimmune Diseases
  - 5.3.4.1. Autoimmune Diseases Biomarker Clinical Phase Outsourcing Services Market, 2018 to 2030 (USD Million)
- 5.3.5. Others
  - 5.3.5.1. Others Biomarker Clinical Phase Outsourcing Services Market, 2018 to 2030 (USD Million)

Chapter 6. Biomarker Clinical Phase Outsourcing Services Market: End-use Estimates & Trend Analysis

6.1. Biomarker Clinical Phase Outsourcing Services Market, By End-use: Segment Dashboard
6.2. Biomarker Clinical Phase Outsourcing Services Market, By End-use: Movement Analysis
6.3. Biomarker Clinical Phase Outsourcing Services Market Estimates & Forecasts, By End-use, 2018 - 2030
- 6.3.1. Pharmaceutical Companies
  - 6.3.1.1. Pharmaceutical Companies Biomarker Clinical Phase Outsourcing Services Market 2018 to 2030 (USD Million)
- 6.3.2. Biotechnology Companies
  - 6.3.2.1. Biotechnology Companies Biomarker Clinical Phase Outsourcing Services Market 2018 to 2030 (USD Million)
- 6.3.3. Others
  - 6.3.3.1. Others Biomarker Clinical Phase Outsourcing Services Market 2018 to 2030 (USD Million)

Chapter 7. Biomarker Clinical Phase Outsourcing Services Market: Regional Estimates & Trend Analysis

7.1. Regional Market Share Analysis, 2022 & 2030
7.2. Regional Market Dashboard
7.3. Global Regional Market Snapshot
7.4. North America
- 7.4.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
- 7.4.2. U.S.
  - 7.4.2.1. Key Country Dynamics
  - 7.4.2.2. Competitive Scenario
  - 7.4.2.3. Regulatory Framework
  - 7.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030
- 7.4.3. Canada
  - 7.4.3.1. Key Country Dynamics
  - 7.4.3.2. Competitive Scenario
  - 7.4.3.3. Regulatory Framework
  - 7.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030
7.5. Europe
- 7.5.1. UK
  - 7.5.1.1. Key Country Dynamics
  - 7.5.1.2. Competitive Scenario
  - 7.5.1.3. Regulatory Framework
  - 7.5.1.4. UK Market Estimates and Forecasts, 2018 - 2030
- 7.5.2. Germany
  - 7.5.2.1. Key Country Dynamics
  - 7.5.2.2. Competitive Scenario
  - 7.5.2.3. Regulatory Framework
  - 7.5.2.4. Germany Market Estimates and Forecasts, 2018 - 2030
- 7.5.3. France
  - 7.5.3.1. Key Country Dynamics
  - 7.5.3.2. Competitive Scenario
  - 7.5.3.3. Regulatory Framework
  - 7.5.3.4. France Market Estimates and Forecasts, 2018 - 2030
- 7.5.4. Italy
  - 7.5.4.1. Key Country Dynamics
  - 7.5.4.2. Competitive Scenario
  - 7.5.4.3. Regulatory Framework
  - 7.5.4.4. Italy Market Estimates and Forecasts, 2018 - 2030
- 7.5.5. Spain
  - 7.5.5.1. Key Country Dynamics
  - 7.5.5.2. Competitive Scenario
  - 7.5.5.3. Regulatory Framework
  - 7.5.5.4. Spain Market Estimates and Forecasts, 2018 - 2030
- 7.5.6. Denmark
  - 7.5.6.1. Key Country Dynamics
  - 7.5.6.2. Competitive Scenario
  - 7.5.6.3. Regulatory Framework
  - 7.5.6.4. Denmark Market Estimates and Forecasts, 2018 - 2030
- 7.5.7. Sweden
  - 7.5.7.1. Key Country Dynamics
  - 7.5.7.2. Competitive Scenario
  - 7.5.7.3. Regulatory Framework
  - 7.5.7.4. Sweden Market Estimates and Forecasts, 2018 - 2030
- 7.5.8. Norway
  - 7.5.8.1. Key Country Dynamics
  - 7.5.8.2. Competitive Scenario
  - 7.5.8.3. Regulatory Framework
  - 7.5.8.4. Norway Market Estimates and Forecasts, 2018 - 2030
7.6. Asia Pacific
- 7.6.1. Japan
  - 7.6.1.1. Key Country Dynamics
  - 7.6.1.2. Competitive Scenario
  - 7.6.1.3. Regulatory Framework
  - 7.6.1.4. Japan Market Estimates and Forecasts, 2018 - 2030
- 7.6.2. India
  - 7.6.2.1. Key Country Dynamics
  - 7.6.2.2. Competitive Scenario
  - 7.6.2.3. Regulatory Framework
  - 7.6.2.4. India Market Estimates and Forecasts, 2018 - 2030
- 7.6.3. China
  - 7.6.3.1. Key Country Dynamics
  - 7.6.3.2. Competitive Scenario
  - 7.6.3.3. Regulatory Framework
  - 7.6.3.4. China Market Estimates and Forecasts, 2018 - 2030
- 7.6.4. South Korea
  - 7.6.4.1. Key Country Dynamics
  - 7.6.4.2. Competitive Scenario
  - 7.6.4.3. Regulatory Framework
  - 7.6.4.4. South Korea Market Estimates and Forecasts, 2018 - 2030
- 7.6.5. Australia
  - 7.6.5.1. Key Country Dynamics
  - 7.6.5.2. Competitive Scenario
  - 7.6.5.3. Regulatory Framework
  - 7.6.5.4. Australia Market Estimates and Forecasts, 2018 - 2030
- 7.6.6. Thailand
  - 7.6.6.1. Key Country Dynamics
  - 7.6.6.2. Competitive Scenario
  - 7.6.6.3. Regulatory Framework
  - 7.6.6.4. Thailand Market Estimates and Forecasts, 2018 - 2030
7.7. Latin America
- 7.7.1. Brazil
  - 7.7.1.1. Key Country Dynamics
  - 7.7.1.2. Competitive Scenario
  - 7.7.1.3. Regulatory Framework
  - 7.7.1.4. Brazil Market Estimates and Forecasts, 2018 - 2030
- 7.7.2. Mexico
  - 7.7.2.1. Key Country Dynamics
  - 7.7.2.2. Competitive Scenario
  - 7.7.2.3. Regulatory Framework
  - 7.7.2.4. Mexico Market Estimates and Forecasts, 2018 - 2030
- 7.7.3. Argentina
  - 7.7.3.1. Key Country Dynamics
  - 7.7.3.2. Competitive Scenario
  - 7.7.3.3. Regulatory Framework
  - 7.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030
7.8. MEA
- 7.8.1. South Africa
  - 7.8.1.1. Key Country Dynamics
  - 7.8.1.2. Competitive Scenario
  - 7.8.1.3. Regulatory Framework
  - 7.8.1.4. South Africa Market Estimates and Forecasts, 2018 - 2030
- 7.8.2. Saudi Arabia
  - 7.8.2.1. Key Country Dynamics
  - 7.8.2.2. Competitive Scenario
  - 7.8.2.3. Regulatory Framework
  - 7.8.2.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030
- 7.8.3. UAE
  - 7.8.3.1. Key Country Dynamics
  - 7.8.3.2. Competitive Scenario
  - 7.8.3.3. Regulatory Framework
  - 7.8.3.4. UAE Market Estimates and Forecasts, 2018 - 2030
- 7.8.4. Kuwait
  - 7.8.4.1. Key Country Dynamics
  - 7.8.4.2. Competitive Scenario
  - 7.8.4.3. Regulatory Framework
  - 7.8.4.4. Kuwait Market Estimates and Forecasts, 2018 - 2030

Chapter 8. Competitive Landscape

8.1. Market Participant Categorization
- 8.1.1. Innovators
- 8.1.2. Market Leaders
- 8.1.3. Emerging Players
- 8.1.4. Company Market Share Analysis, 2022
8.2. Company Profiles
- 8.2.1. Laboratory Corporation of America Holdings
  - 8.2.1.1. Company Overview
  - 8.2.1.2. Financial Performance
  - 8.2.1.3. Service Benchmarking
  - 8.2.1.4. Strategic Initiatives
- 8.2.2. Parexel International Corporation
  - 8.2.2.1. Company Overview
  - 8.2.2.2. Financial Performance
  - 8.2.2.3. Service Benchmarking
  - 8.2.2.4. Strategic Initiatives
- 8.2.3. ICON plc
  - 8.2.3.1. Company Overview
  - 8.2.3.2. Financial Performance
  - 8.2.3.3. Service Benchmarking
  - 8.2.3.4. Strategic Initiatives
- 8.2.4. Charles River Laboratories
  - 8.2.4.1. Company Overview
  - 8.2.4.2. Financial Performance
  - 8.2.4.3. Service Benchmarking
  - 8.2.4.4. Strategic Initiatives
- 8.2.5. Proteome Sciences
  - 8.2.5.1. Company Overview
  - 8.2.5.2. Financial Performance
  - 8.2.5.3. Service Benchmarking
  - 8.2.5.4. Strategic Initiatives
- 8.2.6. Fujirebio
  - 8.2.6.1. Company Overview
  - 8.2.6.2. Financial Performance
  - 8.2.6.3. Service Benchmarking
  - 8.2.6.4. Strategic Initiatives
- 8.2.7. WuXi AppTec
  - 8.2.7.1. Company Overview
  - 8.2.7.2. Financial Performance
  - 8.2.7.3. Service Benchmarking
  - 8.2.7.4. Strategic Initiatives
- 8.2.8. NorthEast BioAnalytical Laboratories LLC.
  - 8.2.8.1. Company Overview
  - 8.2.8.2. Financial Performance
  - 8.2.8.3. Service Benchmarking
  - 8.2.8.4. Strategic Initiatives
- 8.2.9. Celerion
  - 8.2.9.1. Company Overview
  - 8.2.9.2. Financial Performance
  - 8.2.9.3. Service Benchmarking
  - 8.2.9.4. Strategic Initiatives
- 8.2.10. GenScript ProBio
  - 8.2.10.1. Company Overview
  - 8.2.10.2. Financial Performance
  - 8.2.10.3. Service Benchmarking
  - 8.2.10.4. Strategic Initiatives

簡介目錄圖表

List of Tables

Table 1 List of secondary sources
Table 2 List of Abbreviations
Table 3 North America Biomarker Clinical Phase Outsourcing Services market, by region, 2018 - 2030 (USD Million)
Table 4 North America Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 5 North America Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
Table 6 North America Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
Table 7 U.S. Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 8 U.S. Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
Table 9 U.S. Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
Table 10 Canada Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 11 Canada Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
Table 12 Canada Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
Table 13 Europe Biomarker Clinical Phase Outsourcing Services market, by region, 2018 - 2030 (USD Million)
Table 14 Europe Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 15 Europe Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
Table 16 Europe Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
Table 17 UK Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 18 UK Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
Table 19 UK Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
Table 20 Germany Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 21 Germany Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
Table 22 Germany Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
Table 23 France Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 24 France Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
Table 25 France Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
Table 26 Italy Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 27 Italy Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
Table 28 Italy Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
Table 29 Spain Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area type, 2018 - 2030 (USD Million)
Table 30 Spain Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
Table 31 Spain Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
Table 32 Denmark Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 33 Denmark Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
Table 34 Denmark Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
Table 35 Sweden Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 36 Sweden Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
Table 37 Sweden Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
Table 38 Norway Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 39 Norway Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
Table 40 Norway Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
Table 41 Asia Pacific Biomarker Clinical Phase Outsourcing Services market, by region, 2018 - 2030 (USD Million)
Table 42 Asia Pacific Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 43 Asia Pacific Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
Table 44 Asia Pacific Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
Table 45 China Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 46 China Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
Table 47 China Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
Table 48 Japan Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 49 Japan Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
Table 50 Japan Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
Table 51 India Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 52 India Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
Table 53 Australia Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 54 Australia Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
Table 55 Australia Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
Table 56 South Korea Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 57 South Korea Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
Table 58 South Korea Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
Table 59 Thailand Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
Table 60 Thailand Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 61 Thailand Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
Table 62 Latin America Biomarker Clinical Phase Outsourcing Services market, by region, 2018 - 2030 (USD Million)
Table 63 Latin America Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 64 Latin America Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
Table 65 Latin America Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
Table 66 Brazil Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 67 Brazil Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
Table 68 Brazil Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
Table 69 Mexico Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 70 Mexico Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
Table 71 Mexico Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
Table 72 Argentina Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 73 Argentina Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
Table 74 Argentina Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
Table 75 Middle East and Africa Biomarker Clinical Phase Outsourcing Services market, by region, 2018 - 2030 (USD Million)
Table 76 Middle East and Africa Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 77 Middle East and Africa Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
Table 78 Middle East and Africa Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
Table 79 South Africa Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 80 South Africa Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
Table 81 South Africa Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
Table 82 Saudi Arabia Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 83 Saudi Arabia Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
Table 84 Saudi Arabia Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
Table 85 UAE Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 86 UAE Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
Table 87 UAE Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
Table 88 Kuwait Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 89 Kuwait Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
Table 90 Kuwait Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)

List of Figures

Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Market research approaches
Fig. 4 QFD modeling for market share assessment
Fig. 5 Market formulation & validation
Fig. 6 Commodity flow analysis
Fig. 7 Primary research pattern
Fig. 8 Primary interviews in North America
Fig. 9 Primary interviews in Europe
Fig. 10 Primary interviews in Asia Pacific
Fig. 11 Primary interviews in Latin America
Fig. 12 Primary interviews in MEA
Fig. 13 Market Snapshot
Fig. 14 Segment Snapshot
Fig. 15 Segment Snapshot
Fig. 16 Competitive Landscape Snapshot
Fig. 17 Biomarker Clinical Phase Outsourcing Services market segmentation
Fig. 18 Parent market outlook (2022)
Fig. 19 Related/ancillary market outlook (2022)
Fig. 20 Market driver relevance analysis (Current & future impact)
Fig. 21 Current shared services and outsourcing usage levels
Fig. 22 Market restraint relevance analysis (Current & future impact)
Fig. 23 Porter's five forces analysis
Fig. 24 SWOT analysis, by a factor (political & legal, economic and technological)
Fig. 25 Biomarker Clinical Phase Outsourcing Services Market Biomarker Type outlook: Segment dashboard
Fig. 26 Biomarker Clinical Phase Outsourcing Services: Biomarker Type movement analysis
Fig. 27 Predictive Biomarkers market, 2018 - 2030 (USD Million)
Fig. 28 Prognostic Biomarkers market, 2018 - 2030 (USD Million)
Fig. 29 Safety Biomarkers market, 2018 - 2030 (USD Million)
Fig. 30 Surrogate Endpoints market, 2018 - 2030 (USD Million)
Fig. 31 Biomarker Clinical Phase Outsourcing Services Market Therapeutic Area outlook: Segment dashboard
Fig. 32 Biomarker Clinical Phase Outsourcing Services: Therapeutic Area type movement analysis
Fig. 33 Oncology market, 2018 - 2030 (USD Million)
Fig. 34 Neurology market, 2018 - 2030 (USD Million)
Fig. 35 Cardiology market, 2018 - 2030 (USD Million)
Fig. 36 Autoimmune Diseases market, 2018 - 2030 (USD Million)
Fig. 37 Others market, 2018 - 2030 (USD Million)
Fig. 38 Biomarker Clinical Phase Outsourcing Services market End-use outlook: Segment dashboard
Fig. 39 Biomarker Clinical Phase Outsourcing Services market: End-use movement analysis
Fig. 40 Pharmaceutical Companies market, 2018 - 2030 (USD Million)
Fig. 41 Biotechnology Companies market, 2018 - 2030 (USD Million)
Fig. 42 Others market, 2018 - 2030 (USD Million)
Fig. 43 Regional marketplace: Segment dashboard
Fig. 44 Regional outlook, 2022 & 2030
Fig. 45 North America market, 2018 - 2030 (USD Million)
Fig. 46 U.S. market, 2018 - 2030 (USD Million)
Fig. 47 Canada market, 2018 - 2030 (USD Million)
Fig. 48 Europe market, 2018 - 2030 (USD Million)
Fig. 49 Germany market, 2018 - 2030 (USD Million)
Fig. 50 UK market, 2018 - 2030 (USD Million)
Fig. 51 France market, 2018 - 2030 (USD Million)
Fig. 52 Italy market, 2018 - 2030 (USD Million)
Fig. 53 Spain market, 2018 - 2030 (USD Million)
Fig. 54 Denmark market, 2018 - 2030(USD Million)
Fig. 55 Sweden market, 2018 - 2030 (USD Million)
Fig. 56 Norway market, 2018 - 2030 (USD Million)
Fig. 57 Asia Pacific market, 2018 - 2030 (USD Million)
Fig. 58 China market, 2018 - 2030 (USD Million)
Fig. 59 Japan market, 2018 - 2030 (USD Million)
Fig. 60 India market, 2018 - 2030 (USD Million)
Fig. 61 Australia market, 2018 - 2030 (USD Million)
Fig. 62 South Korea market, 2018 - 2030 (USD Million)
Fig. 63 Thailand market, 2018 - 2030 (USD Million)
Fig. 64 Latin America market, 2018 - 2030 (USD Million)
Fig. 65 Brazil market, 2018 - 2030 (USD Million)
Fig. 66 Mexico market, 2018 - 2030 (USD Million)
Fig. 67 Argentina market, 2018 - 2030 (USD Million)
Fig. 68 Middle East & Africa market, 2018 - 2030 (USD Million)
Fig. 69 South Africa market, 2018 - 2030 (USD Million)
Fig. 70 Saudi Arabia market, 2018 - 2030 (USD Million)
Fig. 71 UAE market, 2018 - 2030 (USD Million)
Fig. 72 Kuwait market, 2018 - 2030 (USD Million)